Research output per year
Research output per year
Personal profile
Side activities
|
Instelling |
Functie |
Tijdvak |
|
Genmab |
President & CEO (sinds 2010) |
1999-heden |
|
Hookipa Pharma Inc |
Voorzitter, raad van commissarissen |
2017-heden |
|
LEO Pharma |
Lid, raad van commissarissen |
2017-heden |
|
Celdara Medical |
Lid, raad van commissarissen |
2012-heden |
|
Thuja Capital Healthcare Fund |
Lid, wetenschappelijke adviesraad |
2006-heden |
|
Capricorn Health-tech Fund |
Lid, adviesraad |
2010-heden |
Side activities
|
Forbion |
Lid Forbion Growth Advisory Group |
2020-heden |
|
Alpha Omega SPAC |
Lid raad van commissarissen |
2020-heden |
|
CPCT |
Lid raad van toezicht |
2020-heden |
|
Edward Jenner Stichting |
Lid raad van toezicht |
2013-heden |
-
Complement is activated by IgG hexamers assembled at the cell surface.
Diebolder, C. A., Beurskens, F. J. M., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M. M., Ugurlar, D., Rosati, S., Heck, A. J. R., van de Winkel, J. G. J., Wilson, I. A., Koster, A. J., Taylor, R. P., Saphire, E. O., Burton, D. R., Schuurman, J., Gros, P. & Parren, P. W. H. I., 2014, In: Science. 343, 6176, p. 1260-1263 4 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.
Labrijn, A. F., Meesters, J., Goeij, B. E., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., van Berkel, P. H. C., van de Winkel, J. G. J., Schuurman, J. & Parren, P. W. H. I., 2013, In: Proceedings of the National Academy of Sciences of the United States of America. 110, 13, p. 5145-5150 6 p.Research output: Contribution to journal › Article › Academic › peer-review
-
IgA EGFR antibodies mediate tumour killing in vivo.
Boross, P., Lohse, S., Nederend, M., Jansen, J. H. M., van Tetering, G., Dechant, M., Peipp, M., Royle, L., Liew, L. P., Boon, L., van Rooijen, N., Bleeker, W. K., Parren, P., van de Winkel, J. G. J., Valerius, T. & Leusen, J. H. W., 2013, In: Embo Molecular Medicine. 5, 8, p. 1213-1216 4 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions
Stemerding, A. M., Kohl, J., Pandey, M. K., Kuipers, A., Leusen, J. H. W., Boross, P., Nederend, M., Vidarsson, G., Weersink, A. J. L., van de Winkel, J. G. J., van Kessel, C. P. M. & van Strijp, J. A. G., 2013, In: Journal of Immunology. 191, 1, p. 353-362 10 p.Research output: Contribution to journal › Article › Academic › peer-review
-
The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius, P., Baerenwaldt, A., Kellner, C., Staudinger, M., Dechant, M., Stauch, M., Beurskens, F. J., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T., Humpe, A., Repp, R., Gramatzki, M., Nimmerjahn, F. & Peipp, M., 2013, In: Leukemia. 27, 1, p. 190-201 12 p.Research output: Contribution to journal › Article › Academic › peer-review